// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, July 15, 2025 /CNW/ -- BioVaxys...
New alternative to soil fumigation controls plant-parasitic nematodes, soilborne pathogens, and pre-emergent weed seeds in all crop soils
DES MOINES, Iowa, July 15, 2025 /PRNewswire/...
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC).
Saint Herblain (France), le 11 juillet 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) allait lever sa restriction temporaire sur la vaccination des personnes âgées de 65 et plus avec le vaccin à dose unique contre le chikungunya IXCHIQ® de Valneva suite à l’achèvement d’une revue complète du vaccin par le comité pour l’évaluation des risques en matière de pharmacovigilance de l’EMA (PRAC).
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International...
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International...
HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina’s common stock to a new non-executive employee on June 18, 2025 (the “Option Grant”).
Oversubscribed round was led by Future Ventures, and included NFX, BOLD Capital Partners, Kendall Capital Partners, Amplify Partners, Base4 Capital and others
Dr. Emilio Emini, former SVP of...
AAP, ACP, APHA, IDSA, MPHA, and SMFM Join Together to Stop Assault on Public Health
BOSTON, July 7, 2025 /PRNewswire/ -- Today, the American Academy...
CINCINNATI, July 4, 2025 /PRNewswire/ -- During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus invading...
SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...
Invivyd Forms SPEAR (Spike Protein Elimination and Recovery) Study Group with Researches to Assess Effects of Monoclonal Antibody Therapy for Long COVID
Market Growth Driven by Rapid Disposable Technology Adoption, Expanding Biopharmaceutical Sector, and Government Support for Bioproduction
REDDING, Calif., June 30, 2025 /PRNewswire/ --According to a...